Optimising outcomes in end-stage heart failure: differences in therapeutic responses between diverse ethnic groups

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart disease exhibits distinct clinical and pathophysiological characteristics between Japanese and Caucasian populations.
• Therapeutic strategies for heart failure, particularly in Western societies, focus on improving mortality rates.

Purpose of the Study:

• To evaluate the potential benefits and risks of vesnarinone therapy in Japanese patients with heart failure, considering population-specific differences.
• To assess whether vesnarinone therapy could be justified for improving quality of life in this population.

Main Methods:

• Re-analysis of findings from the Vesnarinone Trial (VEST).
• Examination of adverse events and mortality associated with vesnarinone use.
• Assessment of risk factors including concomitant digoxin use and presence of bradycardia.

Main Results:

• Vesnarinone use was linked to increased mortality, predominantly within seven months of treatment initiation.
• Higher mortality rates were observed in patients concurrently treated with digoxin or those with severe bradycardia.
• Improvements in cardiac function and symptoms with vesnarinone were associated with an increased risk of sudden death in severe heart failure cases.

Conclusions:

• While vesnarinone might offer quality of life improvements for Japanese heart failure patients, its use requires extreme caution.
• Close medical supervision, including renal function and ECG monitoring, is essential due to significant safety concerns and increased mortality risks.